Gleevec (imatinib mesylate) is a medication used to treat certain types of cancer, including chronic myeloid leukemia (CML), gastrointestinal stromal tumors (GIST), and some types of acute lymphoblastic leukemia (ALL). Gleevec is a targeted therapy that works by inhibiting the activity of a specific enzyme, called tyrosine kinase that is involved in the growth and spread of cancer cells. By blocking the action of this enzyme, Gleevec can slow down or stop the growth of cancer cells, leading to remission or improved symptoms in some patients. It is typically taken as a pill once or twice a day, with or without food, and the dosage may vary depending on the patient's condition and other factors. Common side effects of Gleevec include nausea, vomiting, diarrhea, headache, fatigue, and fluid retention.
Gleevec, also known as imatinib, is a targeted therapy used to treat certain types of cancer, including CML and GIST. It works by inhibiting specific enzymes involved in cancer cell growth and proliferation, leading to improved outcomes for many patients. CML is a type of blood cancer that affects the white blood cells. Prior to the development of Gleevec, CML was difficult to treat and often required a bone marrow transplant. However, since the introduction of Gleevec, the prognosis for patients with CML has significantly improved. For example, a study published in the New England Journal of Medicine reported that 89% of patients with CML who received Gleevec achieved a complete hematologic response, and 76% achieved a complete cytogenetic response after five years of treatment.
GIST is a type of cancer that affects the gastrointestinal tract. Prior to the development of Gleevec, treatment options for GIST were limited, and the prognosis was poor. However, it has been shown to be highly effective in treating GIST. For example, a study published in the Journal of Clinical Oncology reported that 84% of patients with GIST who received Gleevec achieved disease control, and 70% had a progression-free survival of at least two years. While CML and GIST are the most commonly treated cancers with Gleevec, it has also been used to treat other types of cancer, such as ALL, dermatofibrosarcoma protuberans, and hypereosinophilic syndrome.
Prior to the development of Gleevec, treatment options for CML and GIST were limited, and the prognosis for patients was poor. For example, CML was often treated with chemotherapy and interferon, which were not very effective and had significant side effects. In addition, GIST was often treated with surgery, but the cancer often recurred, and there were no effective systemic therapies available.
However, the development of Gleevec has revolutionized the treatment of these cancers. Gleevec works by targeting specific enzymes involved in cancer cell growth and proliferation, leading to improved outcomes for patients. For example, studies have shown that up to 90% of patients with CML who received Gleevec achieved a complete hematologic response, and the majority of patients achieved a complete cytogenetic response after five years of treatment. Similarly, studies have shown that Gleevec is highly effective in treating GIST, with up to 84% of patients achieving disease control and prolonged progression-free survival.
Novartis, the manufacturer of Gleevec, has patent protection for the drug, which has helped to ensure its market success and profitability. Patent protection grants the owner of a new invention or discovery exclusive rights to make, use, and sell the invention or discovery for a certain period of time, typically 20 years from the filing date of the patent application.
New product launches to flourish in the market
Ayvakit is a kinase inhibitor that was approved by the FDA in 2020 for the treatment of GIST. It works by targeting the KIT and PDGFRA proteins, which are involved in the growth and proliferation of cancer cells. Ayvakit has shown efficacy in patients with advanced GIST who have been previously treated with other therapies, including Gleevec. Tasigna is another tyrosine kinase inhibitor that was approved by the FDA in 2017 for the treatment of CML. Like Sprycel, it works by blocking the activity of the BCR-ABL protein. Tasigna is a second-generation tyrosine kinase inhibitor that is more effective and has fewer side effects than Gleevec. Sprycel is a tyrosine kinase inhibitor that was approved by the FDA in 2017 for the treatment of CML. It works by blocking the activity of the BCR-ABL protein, which is involved in the growth and proliferation of cancer cells. Sprycel has shown efficacy in patients who are resistant or intolerant to other tyrosine kinase inhibitors, including Gleevec.
Segment Overview:
By application: The Gleevec market is divided into blood cancer, lung cancer, colorectal cancer, prostate cancer, breast cancer, cervical cancer, head & neck cancer, glioblastoma, malignant meningioma, mesothelioma, melanoma, and others. It is a targeted therapy drug that specifically targets certain enzymes involved in cancer cell growth and proliferation, leading to improved outcomes for many cancer patients. Blood cancer, particularly CML, is the primary indication for Gleevec. Lung cancer, colorectal cancer, prostate cancer, breast cancer, and cervical cancer are some of the most common types of cancer that Gleevec is used to treat. It has also shown promise in the treatment of glioblastoma, malignant meningioma, mesothelioma, and melanoma, which are typically more difficult to treat. With continued R&D, it is likely that Gleevec and other targeted therapies will continue to play an important role in the treatment of cancer.
By region: The Asia-Pacific (APAC) Gleevec market is experiencing significant growth due to several factors. One of the primary reasons is the increasing prevalence of CML) in the region. CML is a type of blood cancer that can be treated with Gleevec. According to a report by the Leukemia & Lymphoma Society, the incidence of CML in the APAC region is expected to rise in the coming years. This has led to an increased demand for Gleevec, driving growth in the APAC market. Another factor contributing to the growth of the APAC Gleevec market is the increasing awareness about the drug's effectiveness. In addition, the growing healthcare infrastructure in the APAC region is also contributing to the growth of the Gleevec market. Many countries in the region are investing heavily in healthcare infrastructure, including hospitals, clinics, and research facilities. This is creating more opportunities for pharmaceutical companies to market and sell their products, including Gleevec.
Competitive analysis and profiles of the major players in the Gleevec market, such as Abbvie Inc., Astellas Pharma Inc., Bristol Myers Squibb Company, Celgene Co., Eli Lilly and Company, F. Hoffmann-La Roche Ltd., Johnson & Johnson, Merck & Co Inc., Novartis AG, and Pfizer Inc. Major players have adopted product launch and acquisition as key developmental strategies to improve the product portfolio of the Gleevec market.
Gleevec, also known as imatinib, is a targeted therapy used to treat certain types of cancer, including CML and GIST. It works by inhibiting specific enzymes involved in cancer cell growth and proliferation, leading to improved outcomes for many patients. CML is a type of blood cancer that affects the white blood cells. Prior to the development of Gleevec, CML was difficult to treat and often required a bone marrow transplant. However, since the introduction of Gleevec, the prognosis for patients with CML has significantly improved. For example, a study published in the New England Journal of Medicine reported that 89% of patients with CML who received Gleevec achieved a complete hematologic response, and 76% achieved a complete cytogenetic response after five years of treatment.
GIST is a type of cancer that affects the gastrointestinal tract. Prior to the development of Gleevec, treatment options for GIST were limited, and the prognosis was poor. However, it has been shown to be highly effective in treating GIST. For example, a study published in the Journal of Clinical Oncology reported that 84% of patients with GIST who received Gleevec achieved disease control, and 70% had a progression-free survival of at least two years. While CML and GIST are the most commonly treated cancers with Gleevec, it has also been used to treat other types of cancer, such as ALL, dermatofibrosarcoma protuberans, and hypereosinophilic syndrome.
Prior to the development of Gleevec, treatment options for CML and GIST were limited, and the prognosis for patients was poor. For example, CML was often treated with chemotherapy and interferon, which were not very effective and had significant side effects. In addition, GIST was often treated with surgery, but the cancer often recurred, and there were no effective systemic therapies available.
However, the development of Gleevec has revolutionized the treatment of these cancers. Gleevec works by targeting specific enzymes involved in cancer cell growth and proliferation, leading to improved outcomes for patients. For example, studies have shown that up to 90% of patients with CML who received Gleevec achieved a complete hematologic response, and the majority of patients achieved a complete cytogenetic response after five years of treatment. Similarly, studies have shown that Gleevec is highly effective in treating GIST, with up to 84% of patients achieving disease control and prolonged progression-free survival.
Novartis, the manufacturer of Gleevec, has patent protection for the drug, which has helped to ensure its market success and profitability. Patent protection grants the owner of a new invention or discovery exclusive rights to make, use, and sell the invention or discovery for a certain period of time, typically 20 years from the filing date of the patent application.
New product launches to flourish in the market
Ayvakit is a kinase inhibitor that was approved by the FDA in 2020 for the treatment of GIST. It works by targeting the KIT and PDGFRA proteins, which are involved in the growth and proliferation of cancer cells. Ayvakit has shown efficacy in patients with advanced GIST who have been previously treated with other therapies, including Gleevec. Tasigna is another tyrosine kinase inhibitor that was approved by the FDA in 2017 for the treatment of CML. Like Sprycel, it works by blocking the activity of the BCR-ABL protein. Tasigna is a second-generation tyrosine kinase inhibitor that is more effective and has fewer side effects than Gleevec. Sprycel is a tyrosine kinase inhibitor that was approved by the FDA in 2017 for the treatment of CML. It works by blocking the activity of the BCR-ABL protein, which is involved in the growth and proliferation of cancer cells. Sprycel has shown efficacy in patients who are resistant or intolerant to other tyrosine kinase inhibitors, including Gleevec.
Segment Overview:
By application: The Gleevec market is divided into blood cancer, lung cancer, colorectal cancer, prostate cancer, breast cancer, cervical cancer, head & neck cancer, glioblastoma, malignant meningioma, mesothelioma, melanoma, and others. It is a targeted therapy drug that specifically targets certain enzymes involved in cancer cell growth and proliferation, leading to improved outcomes for many cancer patients. Blood cancer, particularly CML, is the primary indication for Gleevec. Lung cancer, colorectal cancer, prostate cancer, breast cancer, and cervical cancer are some of the most common types of cancer that Gleevec is used to treat. It has also shown promise in the treatment of glioblastoma, malignant meningioma, mesothelioma, and melanoma, which are typically more difficult to treat. With continued R&D, it is likely that Gleevec and other targeted therapies will continue to play an important role in the treatment of cancer.
By region: The Asia-Pacific (APAC) Gleevec market is experiencing significant growth due to several factors. One of the primary reasons is the increasing prevalence of CML) in the region. CML is a type of blood cancer that can be treated with Gleevec. According to a report by the Leukemia & Lymphoma Society, the incidence of CML in the APAC region is expected to rise in the coming years. This has led to an increased demand for Gleevec, driving growth in the APAC market. Another factor contributing to the growth of the APAC Gleevec market is the increasing awareness about the drug's effectiveness. In addition, the growing healthcare infrastructure in the APAC region is also contributing to the growth of the Gleevec market. Many countries in the region are investing heavily in healthcare infrastructure, including hospitals, clinics, and research facilities. This is creating more opportunities for pharmaceutical companies to market and sell their products, including Gleevec.
Competitive analysis and profiles of the major players in the Gleevec market, such as Abbvie Inc., Astellas Pharma Inc., Bristol Myers Squibb Company, Celgene Co., Eli Lilly and Company, F. Hoffmann-La Roche Ltd., Johnson & Johnson, Merck & Co Inc., Novartis AG, and Pfizer Inc. Major players have adopted product launch and acquisition as key developmental strategies to improve the product portfolio of the Gleevec market.
Gleevec Market, by APPLICATION Report Highlights
| Aspects | Details |
 By APPLICATION |
|
 By Region |
|
 Key Market Players | Merck & Co Inc, Johnson & Johnson, Pfizer Inc., F. Hoffmann-La Roche Ltd., Astellas Pharma Inc., Eli Lilly and Company, Bristol Myers Squibb Company, Celgene Corporation, Abbvie Inc, Novartis AG |
Loading Table Of Content...
